Cardiac complication after experimental human malaria infection: a case report by Nieman, An-Emmie et al.
BioMed  Central
Page 1 of 8
(page number not for citation purposes)
Malaria Journal
Open Access Case report
Cardiac complication after experimental human malaria infection: 
a case report
An-Emmie Nieman1, Quirijn de Mast2, Meta Roestenberg1, Jorien Wiersma1, 
Gheorghe Pop3, Anton Stalenhoef3, Pierre Druilhe4, Robert Sauerwein*1 and 
André van der Ven3
Address: 1Department of Medical Microbiology, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands, 2Department of 
General Internal Medicine, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands, 3Department of Cardiology, Radboud 
University Nijmegen Medical Center, Nijmegen, The Netherlands and 4Unité de Parasitologie Biomédicale, Institut Pasteur, Paris, France
Email: An-Emmie Nieman - a.nieman@vumc.nl; Quirijn de Mast - Q.deMast@aig.umcn.nl; Meta Roestenberg - M.Roestenberg@aig.umcn.nl; 
Jorien Wiersma - j.wiersma@mmb.umcn.nl; Gheorghe Pop - G.Pop@cardio.umcn.nl; Anton Stalenhoef - A.Stalenhoef@aig.umcn.nl; 
Pierre Druilhe - druilhe@pasteur.fr; Robert Sauerwein* - R.Sauerwein@mmb.umcn.nl; André van der Ven - A.vanderVen@aig.umcn.nl
* Corresponding author    
Abstract
A 20 year-old healthy female volunteer participated in a clinical Phase I and IIa safety and efficacy
trial with candidate malaria vaccine PfLSA-3-rec adjuvanted with aluminium hydroxide. Eleven
weeks after the third and last immunization she was experimentally infected by bites of Plasmodium
falciparum-infected mosquitoes. When the thick blood smear became positive, at day 11, she was
treated with artemether/lumefantrine according to protocol. On day 16 post-infection i.e. two days
after completion of treatment, she woke up with retrosternal chest pain. She was diagnosed as
acute coronary syndrome and treated accordingly. She recovered quickly and her follow-up was
uneventful. Whether the event was related to the study procedures such as the preceding
vaccinations, malaria infection or antimalarial drugs remains elusive. However, the relation in time
with the experimental malaria infection and apparent absence of an underlying condition makes the
infection the most probable trigger. This is in striking contrast, however, with the millions of
malaria cases each year and the fact that such complication has never been reported in the
literature. The rare occurrence of cardiac events with any of the preceding study procedures may
even support a coincidental finding.
Apart from acute coronary syndrome, myocarditis can be considered as a final diagnosis, but the
true nature and patho-physiological explanation of the event remain unclear.
Background
Experimental human malaria infections are a well
accepted method for testing efficacy of candidate pre-
erythrocytic malaria vaccines since 1971 [1-5]. The clinical
presentation of experimental human malaria infections is
generally mild and associated with symptoms of uncom-
plicated malaria [1,2]. The most commonly reported
symptoms and laboratory abnormalities are headache,
malaise, fever, thrombocytopaenia and leucopaenia. With
close monitoring and immediate administration of treat-
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ment upon detection of parasitaemia, experimental
human malaria infections have been considered safe and
well-tolerated [1-3].
Here, a cardiac event occurring shortly after treatment is
described in a healthy volunteer participating in a malaria
vaccine phase I/IIa trial.
Case presentation
A 20-year old, healthy female volunteer (medical student)
participated in a double blind randomized phase I condi-
tional IIa trial with the candidate malaria vaccine PfLSA-3-
rec in 2007-2008. The volunteer's medical history was
unremarkable, except for a tonsillectomy at the age of 4
and mild atopic symptoms for which she occasionally
used a nasal corticosteroid. As medication, she also used a
second generation oral contraceptive. Family history
revealed a myocardial infarction in the paternal grandfa-
ther, when 43 years old, and a positive paternal family his-
tory for dyslipidemia. She never smoked or used illicit
drugs. At inclusion, the blood pressure was 135/88
mmHg with a pulse of 64/minute and a body mass index
of 20 kg/m2; the results of the physical examination were
normal. Subsequent blood pressure measurements
yielded values below 130/80 mmHg. ECG and laboratory
tests were normal, including plasma glucose and lipid lev-
els (Table 1).
The volunteer received three immunizations with 30 μg of
LSA-3 recombinant protein adjuvanted with aluminium
hydroxide. Immunizations were administered subcutane-
ously in the upper arm at monthly intervals. Adverse
events after immunization were injection site pain, and
headache with increasing intensity after each immuniza-
tion. The headache after the third vaccination was severe
and accompanied by photophobia; it lasted for two days
and made her keep bed rest.
Permission from the Independent Research Committee
was obtained for proceeding with the phase IIa part of the
trial. Eleven weeks after the last immunization the volun-
teer was exposed to the bites of five mosquitoes infected
with  Plasmodium falciparum (strain NF54). The thick
blood smear became positive eleven days after exposure
(44 parasites/μl, infected red blood cells 0.0012%) and
treatment with 80/480 mg artemether/lumefantrine
(Riamet®) was immediately initiated. The dose was
repeated after 8, 24, 36, 48 and 60 hours. At the time of
treatment onset the volunteer reported headache, fatigue
and myalgia. These symptoms had started at day eight and
nine after exposure. The day after treatment onset the vol-
unteer reported intermittent fever, which had completely
resolved two days later. The highest recorded sublingual
temperature was 39.6°C. Artemether/lumefantrine was
continued until day 14 and blood smears and PCR were
negative on this day. On day 15 she experienced some
shortness of breath when performing physical exercise,
which she attributed to hay fever.
On day 16, two days after completion of treatment and
with a negative blood smear, the volunteer woke up at
5.30 a.m. with retrosternal chest pain characteristic of
angina pectoris, not radiating, not related to respiration or
change of position. Pain was severe during 30 minutes
and at that time accompanied by nausea. The volunteer
called the study doctor who referred her to the cardiolo-
gist. On admission, the volunteer appeared not in acute
distress, blood pressure was 120/80 mmHg, pulse 75/
min, oxygen saturation 100% while breathing ambient air
and temperature was 37.9°C. The jugular venous pressure
was normal, as was the examination of the heart, lungs
and peripheral arteries. The electrocardiogram showed 1
mm ST elevation in leads II, III and AVF and a negative T-
wave in lead V2 (see Additional file 1, 2, 3, 4). A limited
rise and fall of troponin I (peak 11,8 μg/l on day of admis-
sion) and other cardiac enzymes, including CPK, LDH
and AST was found. The results of laboratory investiga-
tions are presented in Table 1.
On admission, chest X-ray was normal and the echocardi-
ogram showed mild hypokinesia of the inferior wall. Car-
diac MRI performed four days after start of the complaints
did not show any abnormalities. A second cardiac MRI
after ten months conducted in a specialized center in the
Netherlands showed absence of aberrant coronaries and
good cardiac function with small patchy sub-epicardial
staining (posterior)-laterally suggestive for myocarditis
(see Additional file 5). A coronary angiography was not
performed.
The volunteer was admitted to the cardiac care unit with a
diagnosis of acute coronary syndrome. Treatment con-
sisted of nitroglycerin, metoprolol, perindopril, calcium
carbasalate, clopidrogel, enoxaparine and acetami-
nophen. Complaints completely resolved within 30 min-
utes after treatment and the further clinical course was
uneventful, e.g. the patient was free of symptoms through-
out a follow-up period of one year. After four days, the
volunteer was discharged from the hospital in good con-
dition. Medications were gradually discontinued after dis-
charge; only calcium carbasalate was continued for six
months. Given the MRI data and evolution so far the
prognosis is currently considered good.
Discussion
A case of limited myocardial necrosis occurring just after
completion of anti-malarial treatment is reported in an
experimentally infected healthy volunteer without obvi-
ous risk factors for cardiovascular disease. A relationship
between the cardiac event and the parasite challenge and/Malaria Journal 2009, 8:277 http://www.malariajournal.com/content/8/1/277
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Table 1: Clinical Laboratory findings
Haematology and 
biochemistry tests
Reference 
range
Screening Admission Adm +1 Adm +2 Adm +3 Adm +4 = 
Discharge
Haemoglobin (mmol/l) 7.3 - 9.7 7.1 6.9 7.1 6.9
Leukocytes (*109/l) 3.5 - 11.0 6.6 7.9 3.9 5.4
Platelets (*109/l) 120 - 350 259 160 254 302
Glucose (mmol/l) 4.0 - 5.5 (fasting) 4.6 4.9
Sodium (mmol/l) 137 - 144 142 140 137
Potassium (mmol/l) 3.4 - 4.6 4.1 3.9 3.9
Creatinin (umol/l) 45 - 90 61 55 60
Urea nitrogen (mmol/l) 3.0 - 7.0 4.9 3.2
Bilirubin (umol/l) ≤ 17 <10 <10
Alkaline phosphatase (U/l) ≤ 120 55 74 66 69 69
Aspartate 
aminotransferase (U/l)
≤ 40 16 132 104 111 89 83
Alanine aminotransferase 
(U/l)
≤ 45 15 137 134 171 166 164
Lactate dehydrogenase 
(U/l)
≤ 450 313 540 534 562 384
gamma GT (U/l) ≤ 35 13 29 39 36 35
Creatinin Kinase (U/l) ≤ 170 296 105 28
Troponin I (ug/l) ≤ 0.20 10.40 2.75 0.20
CRP (mg/l) ≤ 10 26
Cholesterol 
(mmol/l)
4.7 - 6.5 4.0
Triglycerides (mmol/l) 0.8 - 2.0 1.5
HDL cholesterol (mmol/l) 1.10 - 1.70 1.20
LDL cholesterol (mmol/l) ≤ 3.5 2.12
Coagulation assays
INR 0.9-1.1 1.0 1.0
Fibrinogen (mg/l) 2000-4000 4320
Factor VIII activity (%) 60-150 130%Malaria Journal 2009, 8:277 http://www.malariajournal.com/content/8/1/277
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or its treatment seems probable, especially because of the
chronology of the event and the absence of an alternative
explanation. Remarkably however, cardiac complications
are extremely rare in malaria. To date, myocardial infarc-
tion during or after naturally acquired P. falciparum infec-
tion has not been reported, neither in hundreds of
millions of endemic cases, nor in hundreds of thousands
military troops that were temporarily deployed to
endemic areas [6-8]. In Sierra Leone, a patient was
described with angina pectoris and a positive blood slide,
which may have been an incidental finding in an highly
endemic area [9]. Elevated troponins without cardiac
complaints or ECG abnormalities are rare; an elevation
just above threshold was measured in 1 out of 161
malaria patients [10,11]. Finally, a few cases of myocardi-
tis have been reported and only during severe or fatal fal-
ciparum malaria [12-15].
Regarding a possible effect of the anti-malarial treatment,
it should be noted that the cardiac event occurred shortly
after therapeutic administration of artemether/lumefan-
trine. There is no direct evidence for ischemic cardiotoxic-
ity of this drug combination [16] and artemether,
dihydroartemisinin and lumefantrine concentrations in
the volunteer, measured in the Centre Hospitalier Univer-
sitaire Vaudois in Lausanne, Switzerland, were within
therapeutic ranges (Table 1). Desbutyl-lumefantrine lev-
els were elevated according to Hatz and Lefebvre, however
according to McGready these values are normal [17-19].
One case of coronary artery spasm was reported in a 17-
year old male using artemether/lumefantrine, but that
patient's urine was also tested positive for tetrahydrocan-
nabinol, the active substance in marijuana, which may
possibly contribute to this complication [20].
Since 1985, experimental human malaria infections have
been conducted in three centers in 1367 volunteers. No
cardiac complications have been reported, except a case of
myocardial infarction in 2002 whereby a 39-year old male
volunteer developed a myocardial infarction during
malaria treatment by chloroquine, two days following
detection of malaria parasites in a blood smear [2,21], i.e.
Protein C activity (%) 70-150 >100%
Free protein S antigen (%) 55-115 92%
Homocystein (μmol/l) < 13.4 9.3
Antithrombin III (%) 85-120 98%
Factor II mutation negative negative
Factor V (Leiden) mutation negative negative
von Willebrand Factor (%) 50-150 166%
ADAMTS13 activity (%) 60-140 90%
Additional tests
Convalescent 
microbiological tests
adenovirus, RS-virus, influenza virus, mycoplasma pneumonia, Chlamydia, Q-fever, para-influenza, 
enterovirus
Negative
Auto-immune antibodies ANCA, anticardiolipin antibodies, β2 glycoprotein, lupus anticoagulans, anti-heart (rat) antibodies Negative
Toxicology test tetrahydrocannabinol, amphetamine-derivatives, cocaine, diazepam, methadone, tramadol, opiates Negative
Inflammatory parameters Interleukin 6, Interleukin 8 < detection limit
Time after last dose 7 h15 103 h45
Artemether < detection limit < detection limit
Dihydroartemisinin 26.5 ng/ml < detection limit
Lumefantrine 4308 ng/ml and 443 ng/ml
Desbutyl-lumefantrine 40 ng/ml 18 ng/ml
Table 1: Clinical Laboratory findings (Continued)Malaria Journal 2009, 8:277 http://www.malariajournal.com/content/8/1/277
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with a similar chronology as in the above reported case.
However, this volunteer had cardiovascular risk factors
(hypercholesterolaemia and smoking) and the angiogra-
phy, which was performed in this case, revealed a stenosis
of one of the coronary arteries. In retrospect, the reality of
a true parasitaemia was debatable since blood samples
tested by RT-PCR several months later proved to be nega-
tive [2].
A plausible diagnosis in the LSA-3 volunteer is an acute
coronary syndrome, since limited myocardial necrosis
was found as expressed by the small rise and fall of cardiac
enzymes including the most specific one, troponin. Also
chest pain occurred that was mimicking angina pectoris
and that disappeared after treatment with nitrates. Finally
temporary changes on ECG and echocardiography were
found, both corresponding for damage in the inferior
wall. An acute coronary syndrome can occur in patients
with normal or with abnormal coronary arteries.
An acute coronary syndrome associated with coronary
atherosclerosis primarily occurs in patients over the age of
40. Young patients with myocardial infarction secondary
to atherosclerosis usually have multiple risk factors, such
as dyslipidemia, hypertension, smoking, diabetes melli-
tus, obesity and a positive family history [22,23]. In this
volunteer, the only risk factors present is a positive family
history, although not in a first degree family member.
Anomalous coronary arteries are a rare cause of myocar-
dial infarction in young patients [24]. There were, how-
ever, no indications for coronary abnormalities by cardiac
MRI.
Myocardial ischaemia may also occur in patients with
normal coronary arteries. Patients with this condition are
generally younger, female and have no history of angina
pectoris or traditional risk factors for atherosclerosis,
except smoking [25,26]. Although the exact pathogenic
mechanism often remains elusive, various mechanisms
may contribute, e.g. coronary vasospasm, arterial throm-
bosis and hypercoagulability, and inflammation [27].
Variant angina, also Prinzmetal's angina, is caused by cor-
onary vasospasm and might be a possible explanation for
the symptoms in this volunteer. The classic patient is a
young woman without traditional cardiovascular risk fac-
tors, except for tobacco use [28]. In some patients, variant
angina is a manifestation of a more general vasospastic
disorder and associated with Raynaud's phenomenon and
migraine [29]. Although the volunteer has no previous
history of a vasospastic disorder, she experienced severe
migraine-like headache with photophobia after the last
immunization, which may theoretically have been caused
by increased vasospastic sensitivity. Vasospasm may also
be induced by illicit drugs, most notably cocaine, but also
marijuana [30,31]. The volunteer denied to have used rec-
reational drugs and the toxicology screening was negative.
Coronary thrombosis, often secondary to an inherited or
acquired thrombophilia, may also cause a transient coro-
nary obstruction. No inherited thrombophilia was
detected in this volunteer. Acquired thrombophilia may
result from changes in coagulation cascade, endothelial
function and platelets. Hypercoagulability caused by
auto-immune disease, e.g. the antiphopholipid syn-
drome, seems unlikely because antiphospholipid anti-
bodies and the ANCA were negative (Table 1).
Inflammation may result in a transient coagulopathy,
although in this volunteer neither a pronounced pro-
inflammatory state, nor a pronounced coagulopathy were
observed [32]. The volunteer did use an oral contraceptive
which might increase the risk for arterial thrombosis,
although this risk is minimal in young, non-smoking
women [23].
Inflammation also affects endothelial cell function.
Endothelial dysfunction may impair endothelium-
dependent relaxation, induce vasoconstriction and vasos-
pasm and promote platelet adhesion [33,34]. Release of
von Willebrand factor (vWF) may mediate this platelet
adhesion [35]. Endothelial cell activation with adherence
of infected erythrocytes is considered a key factor in the
pathogenesis of a P. falciparum infection. Indeed, the
occurrence of endothelial cell activation with release of
active vWF has previously been demonstrated in early
experimental malaria infections [36]. Increasing evidence
suggests a potential mechanistic role for vWF in the patho-
genesis of acute coronary syndromes[37]. However, sig-
nificant rises in vWF levels have also been demonstrated
in patients with naturally acquired malaria without the
development of any coronary syndromes [38].
Nonetheless, regardless of biological explanations, vari-
ous studies have found recent infections to be associated
with acute coronary syndromes with normal coronary
arteries[39].
A substantial fall in platelet numbers is observed during
the P. falciparum blood stage in experimental malaria, fol-
lowed by a rapid recovery and a transient relative throm-
bocytosis [2,36]. Young platelets are considered to be
more reactive and increased numbers of young platelets
have been reported in patients with myocardial infarction
[40,41].
Finally, histamine is a strong inducer of endothelial cell
activation. The volunteer has an allergic diathesis and the
day before the event she experienced some shortness of
breath, which she attributed to hay fever. In the KounisMalaria Journal 2009, 8:277 http://www.malariajournal.com/content/8/1/277
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syndrome acute coronary syndromes are associated with
mast cell activation and hypersensitivity [42,43].
Changes in endothelial cell function, platelets and the
coagulation system during experimental malaria might
increase the likelihood for an acute coronary syndrome.
However, it should be noted again that these changes also
occur in naturally acquired malaria infections in individ-
uals living in malaria-endemic regions and in non-
immune travelers - both groups in whom acute coronary
syndromes are not encountered.
Another possible diagnosis in this young female is myo-
carditis. Differentiation between acute coronary syn-
drome and myocarditis is difficult since many clinical and
laboratory findings overlap. Because of the young age, the
absence of clear cardiovascular risk factors and the find-
ings by cardiac MRI, myocarditis is a reasonable alterna-
tive diagnosis. A high occurrence of myocarditis has been
found in young patients without risk factors presenting
with a clinical picture of an acute coronary syndrome and
normal coronary arteries [44]. Post-infectious myocarditis
can be associated with cardiac events especially in combi-
nation with viral infections [45-49]. Convalescent titers in
the patient were negative, neither confirming nor exclud-
ing viral infection.
In relation to malaria few cases of myocarditis have been
reported, but these reports were limited to patients with
severe or fatal falciparum malaria [12-15]. In uncompli-
cated malaria, with low parasitaemia, as was the case in
this volunteer, myocarditis has never been reported. Vac-
cinations, in particular smallpox have been associated
with myocarditis, though in a small number of cases [49-
52]. The clinical presentation of post-vaccination myocar-
ditis may mimic that of an acute coronary syndrome,
making the diagnosis particularly challenging [48,53]. In
this volunteer, the event occurred rather late at 94 days
after the last LSA3 immunization, which makes the asso-
ciation less likely. In such case, a boost of anti-LSA3 anti-
bodies by the malaria challenge would have been
expected, which was not detected.
Conclusion
In conclusion, this volunteer presented with limited myo-
cardial necrosis after an experimental human malaria
infection. Multiple factors possibly contributing to the
cardiac event can be identified, e.g. the preceding vaccina-
tions, malaria infection or antimalarial drugs. However,
the relation of this serious adverse event with the experi-
mental malaria infection is probable because of its rela-
tion in time and apparent absence of underlying illness;
this is in striking contrast, however, with the millions of
malaria cases each year and the fact that such complica-
tion has never been reported in literature. The rare occur-
rence of cardiac events with any of the preceding study
procedures may even support a coincidental finding.
Apart from acute coronary syndrome, myocarditis can be
considered as final diagnosis but the true nature and
patho-physiological explanation of the event remain
unclear.
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